RE: ahp123 - Answer your own question.
You pose a 'question' assuming facts that are not facts and imply that the only possible explanation is a failed trial. All the while ignoring everything else that has happened both before and after the date you set as your benchmark.
There are a limited number of possibilities for the data, given what we already know from the blinded data. Based solely on the blinded data, DC-Vax can probably show sufficient efficacy to get approved in those countries that have already signified that the endpoints have been changed. Meaning even a worst-case scenario is probably pretty positive.
There are plenty of possible reasons for not disclosing the data, including a partnership deal, a buyout, waiting on publication in a medical journal, etc. I have no idea which if any of these reasons is behind their decision to hold off on public disclosure but I have my guesses based on what they have said and done up to this point.
If the trial failed or the results were far below expectations, then how do you explain everything else they have been doing? Why rush the completion of Sawston? Why buy Flaskworks? Why gear up for production of a treatment that will never be approved?
For those still clinging to their ridiculous pump-and-dump narrative, your posts are totally divorced from reality. Having prosecuted pump-and-dump penny stock schemes, I can tell you that no one spends more than a decade building up a company and running a bunch of clinical trials as part of their p&d. And really, where is the pump? The company isn't flooding us with rosy PRs and cheery estimates a dozen times a day. How about the dump? Why isn't management dumping their tens of millions of shares? I mean really, the company somehow hoodwinked some of the leading oncology practitioners in the world with fake data about a trial they are running for more than a decade? All those fake patients on Facebook and Twitter who what, never had cancer?
Anyone selling their shares right now is a sucker or a bad gambler. We have come way too far and are far too close to the finish unless you are making a tax move or your cash position is too perilous.
